Myoglobin(1) (1)
Myoglobin
Normal Range: 0-85 ng/ml
Used in the early evaluation of suspected myocardial infarction (MI).
Diagnosis of disease or injury in skeletal muscle; myoglobin is an oxygen-binding protein in cardiac and skeletal muscle.
Elevated levels are due to trauma, inflammation or ischemic changes in non-cardiac skeletal muscles; can reach high levels in sudden or severe muscle injury.
Excretion & Toxicity: Myoglobin is excreted in urine and is nephrotoxic.
Increased Levels:
Myocardial infarction
Skeletal muscle inflammation
Malignant hyperthermia
Muscular dystrophy
Skeletal muscle ischemia or trauma
Rhabdomyolysis
Seizures
Decreased Levels: Polymyositis
Prostate-specific Antigen (PSA)
Normal Range: <4 ng/ml
Used for early detection screening of prostatic cancer; nearly 90% of significant cancers detected with rectal exams.
Also used to monitor disease post-treatment.
PSA is a glycoprotein, normally found in prostatic epithelial cell cytoplasm; levels rise in prostatic cancer.
Increased Levels:
Prostate cancer
Benign prostatic hyperplasia (BPH)
Prostatitis
CA 19-9
Normal Range: 37 U/ml
Tumor marker for pancreatic or hepatobiliary cancer; used for diagnosis, treatment response evaluation, and monitoring.
CA 19-9 is a carbohydrate cell-surface antigen found on cancer cell surfaces.
Elevated levels support the diagnosis of pancreatic cancer when a pancreatic mass or biliary obstruction is present.
Increased Levels:
Pancreatic carcinoma
Hepatobiliary carcinoma
Pancreatitis
Cholecystitis
Cirrhosis
Gastric cancer
Colorectal cancer
Gallstones
Lung cancer
CA 125
Normal Range: 0-35 U/ml
Used in detection of ovarian cancer; also to determine disease extent & monitor treatment response.
High sensitivity and specificity for ovarian cancer; elevated in over 80% of cases.
It aids diagnosis, but is not solely diagnostic for ovarian cancer.
Increased Levels:
Ovarian cancer
Pancreatic cancer
Colon cancer
Lung cancer
Peritoneal carcinomatosis
Non-ovarian female genital tract cancer
Breast cancer
Lymphoma
Prothrombin Time (PT)
Normal Findings: 11.0-12.5 seconds
Full anticoagulant therapy: > 1.5-2.0 times control value; critical values: > 20 seconds.
Evaluates adequacy of the extrinsic system and common pathway in the clotting mechanism.
Increased Levels:
Liver disease
Hereditary factor deficiencies
Vitamin K deficiency
Bile duct obstruction
Coumadin ingestion
Disseminated intravascular coagulation (DIC)
Massive blood transfusion
Salicylate intoxication
Partial Thromboplastin Time, Activated (APTT)
Normal Findings: 30-40 seconds
Patients on anticoagulant therapy: 1.5-2.5 times control value.
Assesses intrinsic system and common pathway of clot formation; monitors heparin therapy.
Drugs that May Prolong APTT:
Antihistamines
Ascorbic acid
Chlorpromazine
Heparin
Salicylates
Increased Levels:
Congenital clotting factor deficiencies (hemophilia, hypofibrinogenemia)
Cirrhosis of the liver
Vitamin K deficiency
Disseminated intravascular coagulation (DIC)
Heparin or Coumadin administration
Decreased Levels: Early stages of DIC, extensive cancer.